Atrium Therapeutics, Inc.RNA
NasdaqGS•Healthcare•Biotechnology
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc. (RNA) reported trailing twelve months revenue of $0 as of March 2026.
Atrium Therapeutics, Inc. generated $0 in TTM net income, with quarterly EBITDA of $-17.13M. The operating margin stands at -88.0%.
The spread between operating margin (-88.0%) and net margin (-84.7%) indicates tight cost control with minimal non-operating drag.
RNA trades at a P/S of N/A. The price-to-book ratio of 1.0x suggests the stock trades below its book value.
The company reported negative free cash flow of $-33.24M, indicating cash consumption over the period. The balance sheet shows $292.36M in total assets with no in long-term debt against $234.10M in stockholders equity. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation